hypertrophy), or with elements of CKD-MBD (Vitamin D, iPTH, Ca, P, CaXP) we found no correlation. sKlotho showed a positive correlation with hemodialysis efficiency (eKTV) (r¼0.26, p-0.04), but no correlation with hemodialysis duration. When we classified patients according to median sKlotho level, we found out that patients with sKlotho> 333.398 pg/ml had significantly higher level of hemoglobin (11.2 vs. 10.6 g/dl, p¼0.017). Patients with higher levels of sKlotho showed a decreased risk of mortality, however not statistically significant. We found a higher risk of all cause mortality in patients with diabetes mellitus (OR 6.9, 95% CI-1.6924 to 28.1469, p¼0.007) and with left ventricular hypertrophy (OR 12.4, 95% CI-1.5135 to 102.9073, p¼0.01). Conclusions: In our study, higher levels of sKlotho were associated to a better controlled anemia, a better hemodialysis efficiency, the absence of signs of coronary heart disease on ECG, but not with an increased 2 year survival in hemodialysis patients.